Drug Trial Radar · NCT07783503
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Nov 13, 2026
Study completion Nov 15, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effect of multiple doses of phenytoin, a strong cytochrome P450 (CYP)3A4 inducer, and itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetic (PK) profile of DAK539 (hereafter referred to as pelabresib) after a single dose in healthy participants. In addition, the safety and tolerability of a single dose of pelabresib with and without the co-administration of itraconazole or phenytoin will be evaluated.
Conditions
- Healthy Participants
Interventions
PelabresibDrug
Oral dosing
PhenytoinDrug
Oral dosing
ItraconazoleDrug
Oral dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 and 2: Maximum observed plasma concentration (Cmax) of pelabresibTime frame: From pre-dose up to 48 or 72 hours after pelabresib administration
- Part 1 and 2: Area under the plasma concentration-time curve from time 0 to the last measurable concentration sampling time (AUClast) of pelabresibTime frame: From pre-dose up to 48 or 72 hours after pelabresib administration
- Part 1 and 2: Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of pelabresibTime frame: From pre-dose up to 48 or 72 hours after pelabresib administration
- Part 1 and 2: Time to reach maximum plasma concentration (Tmax) of pelabresibTime frame: From pre-dose up to 48 or 72 hours after pelabresib administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Nottingham, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.